Compare VTSI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | JSPR |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.1M | 23.1M |
| IPO Year | 1999 | N/A |
| Metric | VTSI | JSPR |
|---|---|---|
| Price | $4.65 | $1.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $5.00 | ★ $15.50 |
| AVG Volume (30 Days) | 80.4K | ★ 579.3K |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $185,971.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.30 | N/A |
| P/E Ratio | $235.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.55 | $0.62 |
| 52 Week High | $7.47 | $7.19 |
| Indicator | VTSI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 50.87 |
| Support Level | $4.63 | $0.62 |
| Resistance Level | $5.15 | $1.44 |
| Average True Range (ATR) | 0.26 | 0.11 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 79.72 | 76.05 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of the judgmental use of force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company sells and supports the use of force training and marksmanship firearms training systems and accessories for law enforcement, military, or civilian use. Company's The product lany includes simulators, upgrade components, scenarios, scenario software, recoil kits, Threat Fire, and other accessories.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.